Relevance of Regulatory T Cells during Colorectal Cancer Development

被引:53
作者
Olguin, Jonadab E. [1 ,2 ]
Medina-Andrade, Itzel [1 ,2 ]
Rodriguez, Tonathiu [1 ]
Rodriguez-Sosa, Miriam [1 ]
Terrazas, Luis I. [1 ,2 ]
机构
[1] Univ Nacl Autonoma Mexico, Fac Estudios Super FES Iztacala, Lab Nacl Salud Diagnost & Mol Efecto Ambiental En, Av Barrios 1, Tlalnepantla 54090, Mexico
[2] UNAM, FES Iztacala, Unidad Biomed, Av Barrios 1, Tlalnepantla 54090, Mexico
关键词
regulatory T cells; colorectal cancer; animal models; clinical trial; phenotypic plasticity; TUMOR-ASSOCIATED MACROPHAGES; INFLAMMATORY-BOWEL-DISEASE; COLON-CANCER; TGF-BETA; CHEMOKINE PRODUCTION; ANTITUMOR IMMUNITY; LYMPHOCYTES-T; RUNX PROTEINS; MAST-CELLS; SUPPRESSION;
D O I
10.3390/cancers12071888
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, there has been a significant increase in the study of own and foreign human factors favoring the development of different types of cancer, including genetic and environmental ones. However, the fact that the immune response plays a fundamental role in the development of immunity and susceptibility to colorectal cancer (CRC) is much stronger. Among the many cell populations of the immune system that participate in restricting or favoring CRC development, regulatory T cells (Treg) play a major role in orchestrating immunomodulation during CRC. In this review, we established concrete evidence supporting the fact that Treg cells have an important role in the promotion of tumor development during CRC, mediating an increasing suppressive capacity which controls the effector immune response, and generating protection for tumors. Furthermore, Treg cells go through a process called "phenotypic plasticity", where they co-express transcription factors that promote an inflammatory profile. We reunited evidence that describes the interaction between the different effector populations of the immune response and its modulation by Treg cells adapted to the tumor microenvironment, including the mechanisms used by Treg cells to suppress the protective immune response, as well as the different subpopulations of Treg cells participating in tumor progression, generating susceptibility during CRC development. Finally, we discussed whether Treg cells might or might not be a therapeutic target for an effective reduction in the morbidity and mortality caused by CRC.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 135 条
[1]  
Abron Jessicca D, 2018, Oncotarget, V9, P17928, DOI 10.18632/oncotarget.24730
[2]   Adenomatous Polyposis Coli Defines Treg Differentiation and Anti-inflammatory Function through Microtubule-Mediated NFAT Localization [J].
Aguera-Gonzalez, Sonia ;
Burton, Oliver T. ;
Vazquez-Chavez, Elena ;
Cuche, Celine ;
Herit, Floriane ;
Bouchet, Jerome ;
Lasserre, Remi ;
del Rio-Iniguez, Iratxe ;
Di Bartolo, Vincenzo ;
Alcover, Andres .
CELL REPORTS, 2017, 21 (01) :181-194
[3]   Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APCmin/+ mice [J].
Akeus, Paulina ;
Szeponik, Louis ;
Ahlmanner, Filip ;
Sundstrom, Patrik ;
Alsen, Samuel ;
Gustavsson, Bengt ;
Sparwasser, Tim ;
Raghavan, Sukanya ;
Quiding-Jarbrink, Marianne .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (07) :1067-1077
[4]   Treg-cell depletion promotes chemokine production and accumulation of CXCR3+ conventional T cells in intestinal tumors [J].
Akeus, Paulina ;
Langenes, Veronica ;
Kristensen, Jonas ;
von Mentzer, Astrid ;
Sparwasser, Tim ;
Raghavan, Sukanya ;
Quiding-Jarbrink, Marianne .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2015, 45 (06) :1654-1666
[5]   Altered chemokine production and accumulation of regulatory T cells in intestinal adenomas of APCMin/+ mice [J].
Akeus, Paulina ;
Langenes, Veronica ;
von Mentzer, Astrid ;
Yrlid, Ulf ;
Sjoling, Asa ;
Saksena, Pushpa ;
Raghavan, Sukanya ;
Quiding-Jarbrink, Marianne .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (08) :807-819
[6]   Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer [J].
Anagnostou, Valsamo K. ;
Brahmer, Julie R. .
CLINICAL CANCER RESEARCH, 2015, 21 (05) :976-984
[7]  
ASHWELL JD, 1986, J IMMUNOL, V137, P2572
[8]   Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma [J].
Attia, P ;
Maker, AV ;
Haworth, LR ;
Rogers-Freezer, L ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :582-592
[9]   The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation [J].
Bardhan, Kankana ;
Anagnostou, Theodora ;
Boussiotis, Vassiliki A. .
FRONTIERS IN IMMUNOLOGY, 2016, 7
[10]   iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells [J].
Bellone, Matteo ;
Ceccon, Monica ;
Grioni, Matteo ;
Jachetti, Elena ;
Calcinotto, Arianna ;
Napolitano, Anna ;
Freschi, Massimo ;
Casorati, Giulia ;
Dellabona, Paolo .
PLOS ONE, 2010, 5 (01)